Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
immunotherapy gene therapy |
| gptkbp:administeredBy |
intravenous infusion
specialized centers |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XL08
|
| gptkbp:blackBoxWarning |
cytokine release syndrome
neurological toxicities |
| gptkbp:brand |
gptkb:Yescarta
|
| gptkbp:CASNumber |
gptkb:1805230-56-4
|
| gptkbp:cost |
high
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:developer |
gptkb:Kite_Pharma
|
| https://www.w3.org/2000/01/rdf-schema#label |
Axicabtagene ciloleucel
|
| gptkbp:indication |
relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
|
| gptkbp:KEGGID |
D11041
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
genetically modified autologous T cells
targets CD19 antigen |
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:prescriptionRequired |
https://www.ema.europa.eu/en/documents/product-information/yescarta-epar-product-information_en.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125643s019lbl.pdf |
| gptkbp:PubChem_CID |
gptkb:CHEMBL4297599
gptkb:DB13963 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
cytokine release syndrome
neurological toxicities |
| gptkbp:source |
autologous T cells
|
| gptkbp:storage |
cryopreserved
|
| gptkbp:target |
gptkb:CD19
|
| gptkbp:type |
chimeric antigen receptor T-cell therapy
|
| gptkbp:UNII |
6H4E9E3A5T
|
| gptkbp:usedFor |
gptkb:large_B-cell_lymphoma
gptkb:primary_mediastinal_large_B-cell_lymphoma diffuse large B-cell lymphoma high grade B-cell lymphoma transformed follicular lymphoma |
| gptkbp:bfsParent |
gptkb:CAR-T_cell_therapies
|
| gptkbp:bfsLayer |
6
|